Mayne Pharma Group Limited announced it has appointed Mr. Shawn Patrick O'Brien as Managing Director effective from 1 October 2022. This follows from the previously announced retirement of Mr. Scott Richards and a comprehensive search for a successor. Mr. O'Brien has more than 35 years of global pharmaceutical industry experience building successful enterprises.

He is currently founding partner of Key BioPharma Partners providing advice to life science companies and capital providers. He was previously the Chairman and CEO of Genomind Inc., a personalised mental health platform company, and CEO of publicly listed Cipher Pharmaceuticals Inc., a specialty pharmaceutical company with a portfolio of commercial stage dermatology products. He has also been President and CEO of three private biotechs including AltheRx Pharmaceuticals; Profectus BioSciences and Solstice Neurosciences.

Mr. O'Brien held multiple senior leadership roles at AstraZeneca, one of the largest global pharmaceutical companies. At AstraZeneca he was responsible for key brands such as FASLODEX®, SYMBICORT®, PULMICORT® and SEROQUEL® which all became billion-dollar brands. Mr. Richards will cease to be Managing Director and a member of the Board of Directors of Mayne Pharma with effect from 1 October 2022.

Mr. Richards will remain an employee until 30 November to help ensure a well-managed transition to the new CEO. Shawn Patrick O'Brien is the founding partner of Key BioPharma Partners. Previously he was the Chairman and CEO of Genomind for three years, President and CEO of Cipher Pharmaceuticals (TSX: CPH) for over two years.

He was also Founder, President and CEO of AltheRx Pharmaceuticals, a private biopharma development company. Other roles held include President and CEO of Profectus BioSciences Inc. a private biotech company focused on the treatment of chronic infections and President and CEO of Solstice Neurosciences, a biotech company focused on the movement disorders market. Mr. O'Brien spent 17 years with AstraZeneca where he held multiple senior leadership positions in Canada and the US including Vice President of Commercial Operations for Emerging Brands, Vice President and Therapy Area Leader, Respiratory and Inflammation and Commercial and Development Group Director for the Oncology Therapeutic area.

Mr. O'Brien began his career at the Upjohn Company of Canada (part of Pfizer). Mr. O'Brien is the Non-executive Chairman of SFA Therapeutics and Alto Pharma. He is a board member and Co-Chair of the Hubert J.P. Schoemaker Classic (golf charity fundraiser) and an advisory board member of Greater Philadelphia Life Sciences Congress.

He was a 9-year Board member of the Crozer Keystone Hospital System, a former board member of Cyrano, LLC and Melanovus LLC. Mr. O'Brien holds a Bachelor of Science in Microbiology and Immunology from the University of Western Ontario.